Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Merck Sharp & Dohme LLC
Eli Lilly and Company
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Shanghai Shengdi Pharmaceutical Co., Ltd
AbbVie
Imunon
Imunon
AstraZeneca
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Genmab
AbbVie
Merck Sharp & Dohme LLC
AstraZeneca
AstraZeneca
M.D. Anderson Cancer Center
University of Alabama at Birmingham
AstraZeneca
Neonc Technologies, Inc.
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Swiss GO Trial Group
TORL Biotherapeutics, LLC
GlaxoSmithKline
Zhejiang Cancer Hospital
ARCAGY/ GINECO GROUP
AbbVie
Women's Hospital School Of Medicine Zhejiang University
Avenzo Therapeutics, Inc.
Maastricht University Medical Center
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Eli Lilly and Company
AGO Study Group
University Health Network, Toronto
The University of Hong Kong
The University of Hong Kong
University of Pittsburgh
The University of Hong Kong
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Shandong Cancer Hospital and Institute
Akeso
Women's Hospital School Of Medicine Zhejiang University
Bio-Thera Solutions
Huabo Biopharm Co., Ltd.
Qilu Hospital of Shandong University